Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Blood Coagulation Tests | 11 | 2020 | 855 | 2.83 | Why? |
| Factor Xa Inhibitors | 8 | 2019 | 490 | 2.34 | Why? |
| Blood Coagulation | 13 | 2019 | 2768 | 2.08 | Why? |
| Drug Monitoring | 7 | 2020 | 1408 | 2.02 | Why? |
| Benzamides | 2 | 2019 | 421 | 1.19 | Why? |
| Pyridines | 4 | 2019 | 680 | 1.09 | Why? |
| Anticoagulants | 13 | 2020 | 9563 | 1.04 | Why? |
| Thrombin | 5 | 2020 | 325 | 1.00 | Why? |
| Antithrombins | 4 | 2018 | 353 | 0.81 | Why? |
| Immunoassay | 5 | 2021 | 4485 | 0.76 | Why? |
| Spectrum Analysis | 1 | 2019 | 112 | 0.76 | Why? |
| Thrombin Time | 2 | 2017 | 46 | 0.73 | Why? |
| Antibodies, Viral | 16 | 2021 | 51949 | 0.61 | Why? |
| Blood Chemical Analysis | 1 | 2019 | 541 | 0.55 | Why? |
| Administration, Oral | 6 | 2019 | 2340 | 0.53 | Why? |
| Dabigatran | 4 | 2018 | 204 | 0.48 | Why? |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 877 | 0.47 | Why? |
| Partial Thromboplastin Time | 6 | 2019 | 436 | 0.47 | Why? |
| Perches | 1 | 2011 | 5 | 0.46 | Why? |
| Thrombosis | 7 | 2021 | 7504 | 0.46 | Why? |
| Aquaculture | 1 | 2011 | 12 | 0.46 | Why? |
| Prothrombin Time | 4 | 2019 | 434 | 0.39 | Why? |
| Serologic Tests | 2 | 2021 | 4359 | 0.38 | Why? |
| Pyridones | 4 | 2018 | 738 | 0.37 | Why? |
| Kinetics | 3 | 2020 | 3238 | 0.35 | Why? |
| Factor Xa | 2 | 2018 | 113 | 0.34 | Why? |
| Thrombocytopenia | 1 | 2021 | 2093 | 0.34 | Why? |
| Hemostasis | 4 | 2020 | 811 | 0.33 | Why? |
| Stress, Physiological | 1 | 2011 | 378 | 0.32 | Why? |
| Vitamin K | 2 | 2019 | 263 | 0.30 | Why? |
| Rivaroxaban | 3 | 2018 | 467 | 0.29 | Why? |
| Heparin | 2 | 2019 | 2600 | 0.29 | Why? |
| Vaccination | 4 | 2021 | 19050 | 0.26 | Why? |
| Pyrazoles | 4 | 2018 | 1791 | 0.26 | Why? |
| Time Factors | 10 | 2021 | 31397 | 0.26 | Why? |
| Warfarin | 2 | 2019 | 402 | 0.26 | Why? |
| Point-of-Care Systems | 1 | 2017 | 2955 | 0.25 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 37182 | 0.23 | Why? |
| Sensitivity and Specificity | 7 | 2021 | 22971 | 0.23 | Why? |
| Calibration | 2 | 2019 | 307 | 0.22 | Why? |
| Extracellular Vesicles | 2 | 2019 | 607 | 0.22 | Why? |
| Factor XIa | 1 | 2019 | 12 | 0.21 | Why? |
| Factor XIIa | 1 | 2019 | 13 | 0.21 | Why? |
| Immunoglobulin G | 5 | 2021 | 21571 | 0.20 | Why? |
| Freezing | 1 | 2019 | 106 | 0.19 | Why? |
| Humans | 42 | 2021 | 930598 | 0.19 | Why? |
| Predictive Value of Tests | 3 | 2019 | 9537 | 0.19 | Why? |
| Immunoglobulin M | 3 | 2021 | 9091 | 0.18 | Why? |
| Reproducibility of Results | 4 | 2020 | 11304 | 0.18 | Why? |
| Clinical Laboratory Techniques | 3 | 2020 | 23402 | 0.18 | Why? |
| Hemorrhage | 4 | 2019 | 3013 | 0.18 | Why? |
| Immunoglobulin A | 2 | 2020 | 3567 | 0.18 | Why? |
| Cardiopulmonary Bypass | 1 | 2019 | 158 | 0.18 | Why? |
| Luminescent Measurements | 2 | 2020 | 924 | 0.18 | Why? |
| Factor X | 1 | 2017 | 18 | 0.17 | Why? |
| Hemoglobinuria, Paroxysmal | 1 | 2019 | 116 | 0.17 | Why? |
| Antibody Formation | 2 | 2021 | 4038 | 0.17 | Why? |
| Capnocytophaga | 1 | 2017 | 18 | 0.17 | Why? |
| Belgium | 2 | 2021 | 2064 | 0.16 | Why? |
| Electrochemical Techniques | 1 | 2020 | 406 | 0.16 | Why? |
| Protein Stability | 1 | 2019 | 756 | 0.16 | Why? |
| Reference Values | 1 | 2019 | 795 | 0.16 | Why? |
| Automation, Laboratory | 1 | 2019 | 536 | 0.15 | Why? |
| Endopeptidases | 1 | 2017 | 228 | 0.15 | Why? |
| Bites and Stings | 1 | 2017 | 91 | 0.15 | Why? |
| Blood Preservation | 1 | 2017 | 191 | 0.15 | Why? |
| Nucleocapsid | 1 | 2020 | 734 | 0.15 | Why? |
| Quality Control | 1 | 2019 | 628 | 0.15 | Why? |
| Thiazoles | 2 | 2018 | 496 | 0.15 | Why? |
| Blood Specimen Collection | 1 | 2019 | 387 | 0.14 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 7868 | 0.14 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.13 | Why? |
| Drug Administration Schedule | 1 | 2021 | 2324 | 0.13 | Why? |
| Adult | 13 | 2021 | 244371 | 0.13 | Why? |
| False Negative Reactions | 1 | 2020 | 1785 | 0.13 | Why? |
| Area Under Curve | 1 | 2020 | 2564 | 0.12 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.12 | Why? |
| Aeromonas hydrophila | 1 | 2011 | 7 | 0.12 | Why? |
| Muramidase | 1 | 2011 | 24 | 0.11 | Why? |
| Chaperonin 60 | 1 | 2011 | 42 | 0.11 | Why? |
| Erythrocytes | 1 | 2017 | 617 | 0.11 | Why? |
| Hematology | 1 | 2018 | 649 | 0.11 | Why? |
| Tandem Mass Spectrometry | 1 | 2017 | 1031 | 0.11 | Why? |
| Male | 14 | 2021 | 367725 | 0.11 | Why? |
| Female | 14 | 2021 | 380317 | 0.10 | Why? |
| HSP70 Heat-Shock Proteins | 1 | 2011 | 113 | 0.10 | Why? |
| Insulin-Like Growth Factor I | 1 | 2011 | 119 | 0.10 | Why? |
| Phosphoproteins | 1 | 2020 | 4346 | 0.10 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.10 | Why? |
| Reagent Kits, Diagnostic | 1 | 2020 | 2149 | 0.10 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.10 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.10 | Why? |
| Venous Thromboembolism | 2 | 2019 | 4273 | 0.10 | Why? |
| Aged | 8 | 2021 | 215776 | 0.10 | Why? |
| Middle Aged | 11 | 2021 | 270681 | 0.10 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.09 | Why? |
| Cross Reactions | 1 | 2020 | 4374 | 0.09 | Why? |
| Peptide Hydrolases | 1 | 2017 | 1269 | 0.09 | Why? |
| Fibrinolytic Agents | 2 | 2019 | 1702 | 0.09 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.09 | Why? |
| Plasma | 1 | 2019 | 1809 | 0.09 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.09 | Why? |
| Thrombophilia | 1 | 2020 | 1935 | 0.09 | Why? |
| Disseminated Intravascular Coagulation | 1 | 2017 | 994 | 0.09 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.09 | Why? |
| Outpatients | 1 | 2020 | 3417 | 0.09 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.09 | Why? |
| Analysis of Variance | 1 | 2011 | 950 | 0.08 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2019 | 9335 | 0.08 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.08 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.07 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.07 | Why? |
| Longitudinal Studies | 1 | 2020 | 9893 | 0.07 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.07 | Why? |
| Atrial Fibrillation | 1 | 2019 | 2320 | 0.07 | Why? |
| Quality Assurance, Health Care | 2 | 2018 | 596 | 0.06 | Why? |
| Biological Variation, Individual | 1 | 2020 | 66 | 0.05 | Why? |
| United Kingdom | 1 | 2021 | 18046 | 0.05 | Why? |
| Hydrocortisone | 1 | 2011 | 1790 | 0.05 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.05 | Why? |
| Plasminogen Activator Inhibitor 1 | 1 | 2020 | 162 | 0.05 | Why? |
| Luminescence | 1 | 2020 | 236 | 0.05 | Why? |
| Ixodes | 1 | 2019 | 58 | 0.05 | Why? |
| Swine | 2 | 2019 | 3352 | 0.05 | Why? |
| Adolescent | 2 | 2020 | 86841 | 0.05 | Why? |
| Ticks | 1 | 2019 | 107 | 0.05 | Why? |
| Centrifugation | 1 | 2018 | 42 | 0.05 | Why? |
| Retrospective Studies | 5 | 2020 | 105322 | 0.05 | Why? |
| Sheep | 1 | 2019 | 420 | 0.04 | Why? |
| Chromatography | 1 | 2018 | 112 | 0.04 | Why? |
| Prothrombin | 1 | 2018 | 149 | 0.04 | Why? |
| International Normalized Ratio | 1 | 2019 | 300 | 0.04 | Why? |
| Cohort Studies | 1 | 2020 | 36005 | 0.04 | Why? |
| Half-Life | 1 | 2017 | 298 | 0.04 | Why? |
| Blood Glucose | 1 | 2011 | 3642 | 0.04 | Why? |
| Catalysis | 1 | 2017 | 253 | 0.04 | Why? |
| Liver | 1 | 2011 | 4007 | 0.04 | Why? |
| Rabbits | 1 | 2019 | 1171 | 0.04 | Why? |
| Laboratories, Hospital | 1 | 2020 | 489 | 0.04 | Why? |
| Blood Proteins | 1 | 2019 | 551 | 0.04 | Why? |
| Biomarkers | 1 | 2019 | 23361 | 0.04 | Why? |
| Fibrinolysis | 1 | 2020 | 521 | 0.04 | Why? |
| Administration, Intravenous | 1 | 2019 | 1115 | 0.04 | Why? |
| Pandemics | 7 | 2020 | 389249 | 0.04 | Why? |
| Transfusion Reaction | 1 | 2017 | 245 | 0.03 | Why? |
| Plasmids | 1 | 2017 | 840 | 0.03 | Why? |
| Erythrocyte Transfusion | 1 | 2017 | 386 | 0.03 | Why? |
| Animals | 4 | 2019 | 78931 | 0.03 | Why? |
| Linear Models | 1 | 2019 | 1914 | 0.03 | Why? |
| Limit of Detection | 1 | 2020 | 2698 | 0.03 | Why? |
| Mass Spectrometry | 1 | 2018 | 1165 | 0.03 | Why? |
| Fibrinogen | 1 | 2017 | 1048 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2017 | 1444 | 0.03 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.03 | Why? |
| Flow Cytometry | 1 | 2019 | 2393 | 0.03 | Why? |
| Host-Pathogen Interactions | 1 | 2011 | 11041 | 0.03 | Why? |
| Family Characteristics | 1 | 2020 | 2551 | 0.02 | Why? |
| Rats | 1 | 2017 | 2764 | 0.02 | Why? |
| Recurrence | 1 | 2019 | 3675 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.02 | Why? |
| Laboratories | 1 | 2020 | 2858 | 0.02 | Why? |
| Double-Blind Method | 1 | 2019 | 5988 | 0.02 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2017 | 5814 | 0.02 | Why? |
| Point-of-Care Testing | 1 | 2018 | 2782 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| International Cooperation | 1 | 2018 | 3436 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Protein Domains | 1 | 2017 | 6563 | 0.02 | Why? |
| Research Design | 1 | 2019 | 5830 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2019 | 10998 | 0.01 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
| Sepsis | 1 | 2017 | 3517 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.01 | Why? |
| Mice | 1 | 2017 | 21357 | 0.01 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.01 | Why? |
| Risk Assessment | 1 | 2019 | 25439 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Treatment Outcome | 1 | 2019 | 51732 | 0.01 | Why? |
| Risk Factors | 1 | 2020 | 71621 | 0.01 | Why? |
Douxfils's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(181)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(87)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_